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Rozilla Sadia Khan, Huda Saleem Abbasi

Abstract
Adenoid cystic carcinoma of the Bartholin gland is a rare
vulval cancer. Available literature suggests an aggressive
nature with protracted clinical symptoms and local
recurrence despite adequate surgical excision with or
without adjuvant radiotherapy. This case demonstrates
the role of neoadjuvant chemotherapy and interstitial
brachytherapy with less radical surgery, in the treatment
of adenoid cystic carcinoma of the Bartholin gland. A 63year-old woman presented in the clinic four months after
the removal of vulvar mass with histopathology report
showing adenoid cystic carcinoma of the Bartholin gland
with positive margins. Clinical examination and imaging
showed local disease extension up to the levator ani and
abutting anal margin. She was given four cycles of
neoadjuvant chemotherapy followed by ipsilateral
hemivulvectomy with inguino-femoral lymphadenectomy
followed by 25 cycles of external beam radiation and three
cycles of interstitial brachytherapy. The patient has been
disease free for more than 30 months. The use of
neoadjuvant chemotherapy in treatment of Bartholin
carcinoma along with conservative surgery and
radiotherapy can be a good treatment strategy as it
reduces the morbidity associated with radical surgery
without recurrence to date.
Keywords: Bartholin gland carcinoma, genital tract
carcinoma, Adeno cystic carcinoma.
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Introduction
Adenoid cystic Bartholin gland carcinoma (BG-ACC) is a
very rarely reported carcinoma having an incidence of
less than 1% of all female genital malignancies and 1-7%
of all vulvar carcinomas.1 Available literature suggests an
aggressive nature with protracted clinical symptoms and
local recurrence despite adequate surgical excision with
or without adjuvant radiotherapy.2 There is no consensus

Aga Khan University Hospital, Karachi, Pakistan.
Correspondence: Rozilla Sadia Khan. e-mail: rozilla.khan@aku.edu
Vol. 70, No. 8, August 2020

Figure: MRI - Bartholin gland ACC, axial view.
regarding the treatment of this carcinoma. This case
demonstrates the role of neoadjuvant chemotherapy in
the treatment of primary Bartholin cancer, reducing the
need for radical vulvectomy.

Case Report
A 68-year-old lady para 2, menopausal for 18 years,
presented with a vulval lump that had developed after
excisional biopsy, at the Aga Khan University Hospital,
Pakistan, in June 2016. She initially noticed a swelling four
months back which was painful and had visited her doctor
multiple times for urinary burning and vulval swelling and
was given antibiotics with no resolution of symptoms.
An excisional biopsy of the mass was done, but she delayed
visiting her doctor postoperatively. On recurrence of the
swelling, she self-referred to the hospital where
histopathological slides were reviewed which confirmed
the diagnosis of adenoid cystic carcinoma (ACC) of
Bartholin gland with perineural invasion and margins
positive for tumour. She had a family history of colorectal
carcinoma as her sister too had the problem. The patient
had not undergone any routine check-ups or prior
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screening.
Clinical examination revealed a mass of 3x2cm that was
partially mobile, hard, non-fluctuant and painful on
palpation at the site of left labia minora. This mass was in
close proximity to the perineal body and anus. Naked eye
examination showed normal vaginal mucosa around the
vaginal introitus. Per speculum examination did not reveal
any abnormality in uterine cervix and vagina. There was
no inguinal lymphadenopathy on examination.
Radiological examination, haematological, biochemical
test and cervical cytology:MRI showed ill-defined
infiltrating abnormal intensity area measuring 3.1x1.4 cm
which was found to have involved the posterior fornix
and left lateral wall of the vagina. It was abutting the
perineal body and infiltrating into left sided ischiorectal
fossa with involvement of levator sling. A few
subcentimeter pelvic and inguinal lymph nodes were
noted. Cervical cytology was negative for intraepithelial
lesion or malignancy. All routine haematological and
biochemical tests were normal.
In view of the close proximity to the anal orifice, the need
of radical vulvectomy with anal excisional procedure and
colostomy was discussed with the patient who opted for
neoadjuvant treatment, and was given four cycles of
chemotherapy with Cylophosphamide, Adriamycin and
Cisplatin. Follow up MRI of the pelvis showed interval
decrease up to 1 cm of the previously seen lesion. After
four cycles of chemotherapy and optimisation, the patient
underwent left hemivulvectomy and left inguinofemoral
lymphadenectomy. Biopsy of the specimen showed a
tumour of 1.5x1 cm; the tumour was found 2 cm away
from labia majora and 1.1 cm away from deep margins.
Medial wall of the vagina and all lymph nodes were found
tumour-free. After one month of surgery the patient
received 25 cycles of 4500cGy of external beam
radiotherapy and four fractions of 12Gray interstitial
brachytherapy. After the treatment, the patient was
followed up at the clinic with three-monthly clinical
examination, six-monthly MRI for first year and then yearly.
For 30 months since the treatment to date, there have
been no signs of recurrence.

Discussion
ACC, first recognised in 1853, is a specific variant of
adenocarcinoma of the salivary and mucous gland.1 It is
found in various locations such as salivary glands, breast,
skin and lungs.1 BG-ACC is a slow growing tumour with
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a tendency for perineural invasion. The perineural invasion
is characteristic and a possible cause for the pruritus and
pain. The average age of patients is 47 years and the most
common symptom is a painful nodule according to the
64 cases reported so far.2 It has been suggested that the
possibility of cancer should be considered when women
over the age of 40 present with a Bartholin's gland
enlargement. 2 Often, there is delay due to initial
misdiagnosis as Bartholin's cyst, inadequately treated by
drainage or marsupialisation. Enlargement of Bartholin's
gland in women older than 40 years old should be
considered malignant until proven otherwise.
There is no consensus regarding the optimal treatment.
In a study by Yang et al radical vulvectomy and simple
excision with or without inguino -femoral
lymphadenectomy were done. Negative resection margin
was achieved in 70% by radical vulvectomy versus 52%
by simple excision.1 The need for inguinofemoral and
pelvic lymph node dissection should not be considered
unless the nodes are clinically and radiologically involved.
If performed, it should at least be limited to the ipsilateral
side of the tumour.3-6
While a primary surgical approach is recommended where
resection is feasible, in some cases, complete resection
may compromise midline structures such as the anus,
clitoris, urethra and vagina resulting in an excessively
mutilating and morbid surgical approach. Neoadjuvant
chemotherapy or in combination with radiotherapy can
avoid radical surgical complications for the patients. The
goal of neoadjuvant treatment is to reduce the size of the
tumour for radiotherapy or surgery, transform the
inoperable tumours into radically resectable ones, avoid
pelvic exenteration and assure a better quality of life.
Furthermore, neoadjuvant treatments cure micrometastatic dissemination of the disease preventing a
significant rate of relapse. 7 In a study by Mousa et al
neoadjuvant chemoradiation was followed by surgical
excision of a BCG adenocystic carcinoma and the patient
has been in remission for three years.8
Adjuvant radiotherapy is recommended if the surgical
resection margins are positive or perineural invasion is
identified. Local recurrence rate was 9.5% after adjuvant
radiotherapy as against 37.5 % for those who did not
receive adjuvant radiation.9
In the present case, the tumour was in close proximity to
the anus, which precludes achieving negative resection
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margins without posterior exenteration. To avoid
complications and psychosexual impact associated with
radical surgery, the options were discussed with the
patient who opted for neoadjuvant chemotherapy with
Cylophosphamide, Adriamycin and Cisplatin followed by
surgical excision. In order to avoid adverse tissue effects
and promote healing radiotherapy for local control was
carried out post operatively. To our knowledge, this is the
first case of this regimen of treatment.
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Conclusion
In conclusion, primary carcinoma of Bartholin's gland is
a very rare malignancy of the vulva. From this case we
learnt that index of suspicion should be very high in
women developing labial mass over 40 years of age, while
treatment should be multimodal with exploration of new
modalities to reduce morbidity and recurrence.
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